ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Second-generation BCR-ABL inhibitors, nilotinib (Tasigna®), dasatinib (Sprycel®), and bosutinib (Bosulif®) (Figure 1), have been approved to treat CML adult patients with acquired resistance to imatinib.8–10